On the other hand, adjuvant therapies, such as capecitabine for triple-negative breast cancer (TNBC) and trastuzumab emtansine for HER2-positive cases, can improve long-term survival in patients with residual disease [61,62]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.